Denali Buyout Validates F-star’s Asset-Centric Model

30 May 2018

Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.

Roots — Denali claims CNS bispecific antibody partner F-star Gamma • Source: Shutterstock

Denali Buyout Validates F-star’s Asset-Centric Model

More from Deals

More from Business